Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Cell Research)
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
HSR24-151: Oncological Outcome of Multimodality Treatment in Ewing Sarcoma
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):HSR24-151. doi: 10.6004/jnccn.2023.7272.NO ABSTRACTPMID:38580294 | DOI:10.6004/jnccn.2023.7272 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Saroj Prasad Sah Arora R Arya D Verma C Tiwari A Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Cell Research)
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
HSR24-151: Oncological Outcome of Multimodality Treatment in Ewing Sarcoma
J Natl Compr Canc Netw. 2024 Apr 5;22(2.5):HSR24-151. doi: 10.6004/jnccn.2023.7272.NO ABSTRACTPMID:38580294 | DOI:10.6004/jnccn.2023.7272 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 5, 2024 Category: Cancer & Oncology Authors: Saroj Prasad Sah Arora R Arya D Verma C Tiwari A Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition
CONCLUSIONS: Our study suggests the targeting of MCs with clinically administered drugs, such as antihistamines, as a promising approach to overcome resistance to immunotherapy in sarcomas.PMID:38578281 | DOI:10.1158/1078-0432.CCR-24-0246 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 5, 2024 Category: Cancer & Oncology Authors: Myrofora Panagi Fotios Mpekris Chrysovalantis Voutouri Andreas G Hadjigeorgiou Chloe Symeonidou Eleni Porfyriou Christina Michael Andreas Stylianou John D Martin Horacio Cabral Anastasia Constantinidou Triantafyllos Stylianopoulos Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma
CONCLUSIONS: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.PMID:38578882 | DOI:10.3233/CBM-230191 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 5, 2024 Category: Cancer & Oncology Authors: Yixin Wen Feng Xu Hui Zhang Source Type: research
